Table 2 Summary of efficacy: overall response and survival
Parameter | XELIRI (n=30) | IRI (n=30) | P-value |
|---|---|---|---|
n (%) | n (%) | ||
Overall response rate | |||
Complete response (CR) | 2 (6.7) | 0 (0.0) | |
Partial response (PR) | 2 (6.7) | 2 (6.7) | |
Stable disease (SD) | 15 (50.0) | 13 (43.3) | |
Progressive disease (PD) | 11 (36.7) | 15 (50.0) | |
Response rate (RR) | 13.3% | 6.7% | 0.389 |
Disease control rate (DCR) | 63.3% | 50.0% | 0.297 |
Progression-free survival (PFS) | |||
Median PFS (95% CI) | 3.7 months (0.3, 7.1) | 2.4 months (2.0, 2.8) | 0.036* |
Hazard ratio (95% CI) | 0.54 (95% CI: 0.30, 0.98) | ||
Overall survival (OS) | |||
9 months survival rate | 60.9% | 32.0% | 0.045* |
Hazard ratio (95% CI) | 0.30 (95% CI: 0.09, 0.99) | ||
Median OS (95% CI) | 10.1 months (7.4, 12.8) | 7.3 months (6.1, 8.5) | 0.107 |
Hazard ratio (95% CI) | 0.63 (95% CI: 0.35, 1.12) | ||
